LSTA Stock Summary and Trading Ideas (Lisata Therapeutics | NASDAQ:LSTA)

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

Lisata Therapeutics trades on the NASDAQ stock market under the symbol LSTA.

As of June 16, 2026, LSTA stock price climbed to $3.49 with 13,798 million shares trading.

LSTA has a beta of -0.65, meaning it tends to be less sensitive to market movements. LSTA has a correlation of 0.01 to the broad based SPY ETF.

LSTA has a market cap of $31.78 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, LSTA traded as high as $5.07 and as low as $1.81.

The top ETF exchange traded funds that LSTA belongs to (by Net Assets): VTI, VXF, DFSU, DCOR.

LSTA has outperformed the market in the last year with a return of +39.9%, while the SPY ETF gained +26.9%. However, in the most recent history, LSTA shares have underperformed the stock market with its stock returning -30.6% in the last 3 month period and -2.5% for the last 2 week period, while SPY has returned +13.6% and -1.1%, respectively.

LSTA support price is $3.29 and resistance is $3.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LSTA shares will trade within this expected range on the day.